An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

@article{Owen2021AnOS,
  title={An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19},
  author={Dafydd R. Owen and Charlotte Allerton and Annaliesa S. Anderson and Lisa M. Aschenbrenner and Melissa Avery and Simon Berritt and Britton W. Boras and Rhonda D. Cardin and Anthony A. Carlo and Karen J. Coffman and Alyssa L Dantonio and Lima S. N. Di and Heather Eng and Rose Ann Ferre and Ketan S. Gajiwala and Scott A Gibson and Samantha E. Greasley and Brett L Hurst and Eugene P. Kadar and Amit S. Kalgutkar and Jack Chang Hung Lee and Jisun Lee and Wei Liu and Stephen W Mason and Stephen Noell and Jonathan J Novak and R. Scott Obach and Kevin Ogilvie and Nandini C Patel and Martin Pettersson and Devendra Kumar Rai and Matthew R Reese and Matthew F Sammons and Jean G. Sathish and Ravita Singh and Claire M. Steppan and Albert E. Stewart and Jamison B. Tuttle and Lawrence W. Updyke and Patrick Robert Verhoest and Liuqing Wei and Qin-bing Yang and Yuao Zhu},
  journal={Science},
  year={2021},
  volume={374},
  pages={1586 - 1593}
}
Description Path to another drug against COVID-19 The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19. Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been… 
View on Science
doi.org
199 Citations
Highly Influential Citations
11
Background Citations
43
Methods Citations
8

199 Citations

Citation Type

Citation Type

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
TLDR
The latest developments of potential small-molecule inhibitors and peptide inhibitors for PLpro and Mpro are examined, and how structural biology greatly facilitates this process is examined.
Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populations
The search for drugs against COVID-19 and other diseases caused by coronaviruses focuses on the most conserved and essential proteins, mainly the main (Mpro) and the papain-like (PLpro) proteases and…
Advances in the Development of SARS-CoV-2 Mpro Inhibitors
TLDR
Although a drug including a SARS-CoV-2 main protease inhibitor has already been commercialized, denoting the importance of this field, more compounds have been demonstrated to be promising potent inhibitors as potential antiviral drugs.
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters
TLDR
Cobicistat, which is an FDA-approved drug booster that blocks the activity of the drug-metabolizing proteins cytochrome P450-3As (CYP3As) and P-glycoprotein (P-gp), inhibits SARS-CoV-2 replication and can enhance the effect of remdesivir, which was one of the first drugs proposed for treatment of Sars-CoVs.
Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19
TLDR
This study provides evidence that S-217622, an antiviral agent that is under evaluation in a phase II/III clinical trial, possesses remarkable antiviral potency and efficacy against SARS-CoV-2 and is a prospective oral therapeutic option for COVID-19.
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
TLDR
This Perspective highlights major achievements in structure-based design and high-throughput screening of SARS-CoV-2 PLpro inhibitors since the beginning of the pandemic and offers the opinion on the knowledge gaps that need to be filled to advance PL Pro inhibitors to the clinic.
Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
TLDR
Mefloquine is demonstrated as a potential inhibitor of SCoV-2 PLpro and its antiviral activity against SCov-2 and it is proposed that HCoV-229E is a suitable surrogate for SCo V-2 in drug-discovery studies.
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron.
TLDR
A series of potent α-ketoamide-containing Mpro inhibitors obtained using the Ugi four-component reaction provide a promising lead compound for oral drug development against SARS-CoV-2, and oral treatment with Y180 displayed a remarkable antiviral potency.
Antiviral Drug Discovery for the Treatment of COVID-19 Infections
TLDR
An overview of the current status and future direction of antiviral drug discovery for treating SARS-CoV-2 infections is presented, covering important antiviral targets such as the viral spike protein, non-structural protein (nsp) 3 papain-like protease, nsp5 main proteases, and the nsp12/nsp7/ nsp8 RNA-dependent RNA polymerase complex.
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
TLDR
Light is shed on the future development of Mpro inhibitors for SARS-CoV-2 and future coronavirus diseases and comment on their druggability or drawbacks that prevent them from becoming drugs.
...
...

References

SHOWING 1-10 OF 53 REFERENCES
SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
TLDR
32 new bicycloproline-containing Mpro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals are designed and synthesized and display excellent antiviral activity both in vitro and in a transgenic mouse model.
Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning
TLDR
A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronav virus disease 2019 (COVID-19).
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
TLDR
A programme of structure-assisted drug design and high-throughput screening identifies six compounds that inhibit the main protease of SARS-CoV-2, demonstrating the ability of this strategy to isolate drug leads with clinical potential.
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
TLDR
The ADME, safety, in vitro, and in vivo antiviral activity data that supports the clinical evaluation of this compound as a potential COVID-19 treatment are presented.
Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery
SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
TLDR
A combinatorial library of fluorogenic substrates with glutamine in the P1 position is synthesized and provided a structural framework for the design of inhibitors as antiviral agents and/or diagnostic tests.
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
TLDR
Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
TLDR
This perspective focuses on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years from all sources, including laboratory synthetic methods, natural products, and virtual screening.
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
TLDR
The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route and work that may provide a basis for development of anticoronaviral drugs.
SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801
TLDR
The results show that therapeutic and prophylactic administration of EIDD-2801, an oral broad spectrum antiviral currently in phase II-III clinical trials, dramatically inhibited SARS-CoV-2 replication in vivo and thus has significant potential for the prevention and treatment of COVID-19.
...
...